Shanghai Henlius Biotech, Inc. (HKG:2696)

Market Cap	41.79B
Revenue (ttm)	6.09B
Net Income (ttm)	873.12M
Shares Out	543.49M
EPS (ttm)	1.61
PE Ratio	47.87
Forward PE	41.35
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,407,249
Average Volume	1,201,706
Open	77.25
Previous Close	76.90
Day's Range	73.80 - 82.75
52-Week Range	15.20 - 82.35
Beta	0.76
RSI	68.65
Earnings Date	Aug 18, 2025

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s diseas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3,515
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2696

Financial Performance

In 2024, Shanghai Henlius Biotech's revenue was 5.72 billion, an increase of 6.11% compared to the previous year's 5.39 billion. Earnings were 820.47 million, an increase of 50.26%.

Financial numbers in CNY